AnnieDe GrootMD

PubMed

• 3 citations
  Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning.
  Emily K Makowski, Tiexin Wang, Jennifer M Zupancic, Jie Huang, Lina Wu, John S Schardt, Stephanie L Elkins, William D Martin, Peter M Tessier, De Groot, A., Anne S De ...> ;Nature Biomedical Engineering. 2024 Jan 1
• Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis.
  Sonia Ricotti, Alberto Sergio Garay, Marina Etcheverrigaray, Gabriel Ignacio Amadeo, William Martin, Eduardo Federico Mufarrege, De Groot, A., Anne S De Groot> ;Clinical Immunology. 2023 Dec 1
• 4 citations
  Immunogenicity risk assessment of synthetic peptide drugs and their impurities.
  Brian J Roberts, Aimee Mattei, Sandra Lelias, Christine Boyle, William D Martin, De Groot, A., Anne S De Groot> ;Drug Discovery Today. 2023 Oct 1
• Specific sequence mutations in a long-lasting rhIFN-α2b version reduceandimmunogenicity and increaseprotein stability.
  Eduardo Federico Mufarrege, Lucía Carolina Peña, Marina Etcheverrigaray, William Martin, De Groot, A., Anne S De Groot> ;Heliyon. 2023 Mar 1
• H1N1 G4 swine influenza T cell epitope analysis in swine and human vaccines and circulating strains uncovers potential risk to swine and humans.
  Swan Tan, Lenny Moise, Douglas S Pearce, Constantinos S Kyriakis, Andres H Gutiérrez, Ted M Ross, Justin Bahl, Anne S De Groot> ;Influenza and Other Respiratory Viruses. 2023 Jan 1
• 2 citations
  Expanding access to COVID-19 testing, vaccination and treatment at a free clinic for uninsured Spanish-speaking adults in Providence, RI.
  Katherine Barry, Johanna A Suskin, Julia Testa, Morgan Leonard, Anne S De Groot> ;Human Vaccines & Immunotherapeutics. 2022 Nov 30
• A story-telling cloth approach to motivating cervical cancer screening in Mali.
  Tiffani Crippin, Karamoko Tounkara, Eliza Squibb, Sarah Beseme, Katherine Barry, Kotou Sangare, Saidou Coulibaly, Pinda Fané, Aliou Bagayoko, Ousmane A Koita, Ibrahima...> ;Frontiers in Public Health. 2022 Jan 1
• 1 citations
  Diversity and evolution of computationally predicted T cell epitopes against human respiratory syncytial virus.
  Jiani Chen, Swan Tan, Vasanthi Avadhanula, Leonard Moise, Pedro A Piedra, Anne S De Groot, Justin Bahl> ;Plos Computational Biology. 2023 Jan 1
• 27 citations
  Use of T cell epitopes for vaccine development.
  H Sbai, A Mehta, A S DeGroot> ;Current Drug Targets. Infectious Disorders. 2001 Oct 31
• 29 citations
  Identification of Subdominant Cytotoxic T Lymphocyte Epitopes Encoded by Autologous HIV Type 1 Sequences, Using Dendritic Cell Stimulation and Computer-Driven Algorithm
  Xia Jin, Caroline G. P. Roberts, Douglas F. Nixon, Jeffrey T. Safrit, Linqi Zhang, Y. X. Huang, Nina Bhardwaj, Bill M. Jesdale, A. S. DeGroot, Richard A. Koup> ;AIDS Research and Human Retroviruses. 2000 Jan 1
• Does human homology reduce the potential immunogenicity of non-antibody scaffolds?
  Sundos Khan, Aimee E Mattei, Sandra Lelias, William D Martin, De Groot, A., Anne S De Groot> ;Frontiers in Immunology. 2023 Jan 1
• 2 citations
  Identification of immunodominant T cell epitopes induced by natural Zika virus infection.
  De Groot, A., Christopher S Eickhoff, Krystal A Meza, Frances E Terry, Chase G Colbert, Azra Blazevic, Andres H Gutiérrez, E Taylor Stone, James D Brien, Amelia K Pint...> ;Frontiers in Immunology. 2023 Jan 1
• 1 citations
  A SARS-CoV-2 NSP7 homolog of a Treg epitope suppresses CD4+ and CD8+ T cell memory responses.
  S M Shahjahan Miah, Sandra Lelias, Andres H Gutierrez, Mitchell McAllister, Christine M Boyle, Lenny Moise, De Groot, A., Anne S De Groot> ;Frontiers in Immunology. 2023 Jan 1
• Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice.
  Leonard Moise, Lauren M Meyers, Hyesun Jang, Mayara Grizotte-Lake, Christine M Boyle, Bethany McGonnigal, Pan Ge, Ted M Ross, Anne S De Groot> ;Human Vaccines & Immunotherapeutics. 2022 Nov 30
• 1 citations
  Meeting Gynecologic Needs and Assuring Adherence to Screening Guidelines at a Student-Run Free Clinic for Uninsured, Low-Income Women.
  Johanna A Suskin, Katherine Barry, Ella Satish, Morgan Leonard, Anne S De Groot> ;Rhode Island Medical Journal. 2022 Jun 1
• 6 citations
  Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models ofImmunity.
  Ann E Sluder, Susan Raju Paul, Leonard Moise, Christina Dold, Guilhem Richard, Laura Silva-Reyes, Laurie A Baeten, Anja Scholzen, Patrick M Reeves, Andrew J Pollard, A...> ;Frontiers in Immunology. 2022 Jan 1
• 3 citations
  Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A Method Using ExistingAlgorithm Infrastructure and a Vision for Future Enhancements.
  Aimee E Mattei, Andres H Gutierrez, William D Martin, Frances E Terry, Brian J Roberts, Amy S Rosenberg, De Groot, A., Anne S De Groot> ;Frontiers in Drug Discovery. 2022 Jan 1
• 15 citations
  Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
  Guilhem Richard, Michael F Princiotta, Dominique Bridon, William D Martin, Gary D Steinberg, Anne S De Groot> ;Expert Review of Vaccines. 2022 Feb 1
• 6 citations
  Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases.
  Sofía Inés Giorgetti, Marina Etcheverrigaray, Frances Terry, William J. Martin, Anne S. De Groot, Natalia Ceaglio, Marcos Oggero, Eduardo Federico Mufarrege> ;Clinical Immunology. 2021 Nov 17
• 3 citations
  Identification and Immune Assessment of T Cell Epitopes in Five Plasmodium falciparum Blood Stage Antigens to Facilitate Vaccine Candidate Selection and Optimization.
  Vinayaka Kotraiah, Timothy W. Phares, Frances Terry, Pooja Hindocha, Sarah E. Silk, Carolyn M. Nielsen, Leonard Moise, Kenneth D. Tucker, Rebecca Ashfield, William D. ...> ;Frontiers in Immunology. 2021 Jul 7
• 10 citations
  Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease
  Anne S. De Groot, Ankit K. Desai, Sandra Lelias, S. M. Shahjahan Miah, Frances Terry, Sundos Khan, Cindy Li, John S. Yi, Matt Ardito, William D. Martin, Priya S. Kishnani> ;Frontiers in Immunology. 2021 Jun 16
• 5 citations
  Recruitment, Training, and Roles of the Bilingual, Bicultural Navegantes: Developing a Specialized Workforce of Community Health Workers to Serve a Low-Income, Spanish...
  Meghan McCarthy, Katherine Barry, Cindy Estrada, Brenda Veliz, Damaris Rosales, Morgan Leonard, Anne S. De Groot> ;Frontiers in Public Health. 2021 Jun 4
• 7 citations
  Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach.
  Karina Winterling, William D. Martin, Anne S. De Groot, Jens Daufenbach, Steffen Kistner, Jörg Schüttrumpf> ;Journal of Thrombosis and Haemostasis. 2021 Jun 1
• 18 citations
  Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation
  Lauren M. Meyers, Andres H. Gutierrez, Christine M. Boyle, Frances Terry, Bethany G. McGonnigal, Andres Salazar, Michael F. Princiotta, Wiliam D. Martin, Anne S. De Gr...> ;NPJ Vaccines. 2021 May 13
• 4 citations
  Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival.
  Guilhem Richard, Anne S. De Groot, Gary D. Steinberg, Tzintzuni Garcia, Alec Kacew, Matthew Ardito, William D. Martin, Gad Berdugo, Michael F. Princiotta, Arjun Vasant...> ;Scientific Reports. 2021 May 11
• Join now to see all

Journal Articles

• In Silico Vaccine Design: Accelerating the Response to BioThreats and Emerging Infectious Disease  
  Lenny Moise, Sarah Beseme, and Anne S. De Groot, IQT Quarterly, 1/1/2016
• C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells  
  De Groot AS, Ross TM, Levitz L, Messitt TJ, Tassone R, Boyle CM, Vincelli AJ, Moise L, Martin W, Knopf PM, Immunol Cell Biol, 1/1/2015
• Aspartate-beta-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma  
  Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR, Vaccine, 1/1/2015
• In silico Prediction of Immunogenic T Cell Epitopes of Leishmania donovani donovani GP63 Protein: an Alternative Approach for Anti-parasite Vaccine Development  
  Khalil E A G, J J Vaccine Vaccination, 1/1/2015
• Barriers to Health Insurance Pre- and Post-Affordable Care Act Implementation in Providence, RI  
  Pigoga, Jennifer; Kibria, Farzana; Pinilla ,Mauricio; Bicki, Alexandra: Joseph, Valerie; De Groot, Anne S, Rhode Island Medical Journal, 1/1/2015
• Identification and Retrospective Validation of T-cell Epitopes in the Hepatitis C Virus Genotype 4 Proteome: An Accelerated Approach towards Epitope-Driven Vaccine Dev...  
  Abdel-Hady KM, Gutierrez AH, Terry F, Desrosiers J, De Groot AS, Azzazy HM, Hum Vaccin Immunother, 1/24/2014
• Identification and Retrospective Validation of T-cell Epitopes in the Hepatitis C Virus Genotype 4 Proteome: An Accelerated Approach towards Epitope-Driven Vaccine Dev...  
  Abdel-Hady KM, Gutierrez AH, Terry F, Desrosiers J, De Groot AS, Azzazy HM, Hum Vaccin Immunother., 1/24/2014
• HCV Epitope, Homologous to Multiple Human Protein Sequences, Induces a Regulatory T Cell Response in Infected Patients  
  Losikoff PT, Mishra S, Terry F, Gutierrez A, Ardito MT, Fast L, Nevola M, Martin WD, Bailey-Kellogg C, De Groot AS, Gregory SH, J Hepatol, 1/22/2014
• ICoVax 2013: the 3rd ISV Pre-conference Computational Vaccinology Workshop  
  He Y, De Groot AS, BMC Bioinformatics, 1/19/2014
• CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production  
  Gutierrez AH, Bailey-Kellogg C, DaSilva K, Terry F, Ardito M, Moise L, Martin W, De Groot AS, 1/14/2014
• CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production  
  Gutierrez AH, Bailey-Kellogg C, DaSilva K, Terry F, Ardito M, Moise L, Martin W, De Groot AS, Biotechnology and Bioengineering, 1/14/2014
• Dendritic cell-mediated, DNA-based vaccination against hepatitis C induces the multi-epitope-specific response of humanized, HLA transgenic mice  
  Mishra S, Lavelle BJ, Desrosiers J, Ardito MT, Terry F, Martin WD, De Groot AS, Gregory SH, PLoS One, 1/11/2014
• Assessment of Hypertension Guidelines Adherence at a Free Clinic Serving a Predominantly Latino Population in Providence, RI  
  Kibria F., Peters, J. L., Shulman, C., Joseph, V., & De Groot, A. S., Rhode Island J. Medicine, 1/1/2014
• HPV Knowledge and Vaccine Acceptedness in a Low-income Hispanic Population  
  Chau J, Kibria F, Landi M, Reilly M, Medeiros T, Johnson H, Yekta S, De Groot AS, R I Med J, 1/1/2014
• Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage  
  Lu He, Anne S De Groot, Andres H Gutierrez, William D Martin, Lenny Moise and Chris Bailey-Kellogg, BMC Bioinformatics, 1/1/2014
• VaxCelerate II: Rapid Development of a Self-Assembling Vaccine for Lassa Fever  
  Leblanc P, Moise L, Luza C, Chantaralawan K, Lezeau L, Yuan J, Field M, Richer D, Boyle C, Martin B, et al, 1/1/2014
• Tregitopes: An Immunomodulation Powerhouse  
  Leslie P Cousens, PhD; Anne S De Groot, MD; Nader Najafian; William D Martin, Hum Immunol, 1/1/2014
• Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection  
  Moise L, Terry F, Gutierrez AH, Tassone R, Losikoff P, Gregory SH, Martin WD, De Groot AS, Frontiers in Microbiology, 1/1/2014
• Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se  
  Yan Su, Robert Rossi, Anne S. De Groot, and David W. Scott, J. Leukocyte Biology, 1/31/2013
• Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se  
  Yan Su, Robert Rossi, Anne S. De Groot, and David W. Scott, J. Leukocyte Biology. J Leukoc Biol., 1/31/2013
• Elevated antigen-specific Th2 type response is associated with the poor prognosis of hand, foot and mouth disease  
  Wei R, Xu L, Zhang N, Zhu K, Yang J, Yang C, Deng C, Zhu Z, De Groot AS, Altmeyer R, Zeng M, Leng Q, Virus Res, 1/22/2013
• Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice  
  Leonard Moise, Ryan Tassone, Howard Latimer, Frances Terry, Lauren Levitz, John P. Haran, Ted M. Ross, Christine Boyle, William D. Martin, Anne S. De Groot, Hum Vaccin Immunother, 1/17/2013
• Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes  
  Hui, DJ, Basner-Tschakarjan E., Chen Y., Davidson RJ, Buchlis G, Yazicioglu M, Pien, GC Finn JD Haurigot V, Tai A, Scott DW, Cousens LP, Zhou S, De Groot AD, Mingozzi F, Blood. Mol Ther, 1/16/2013
• Adherence to American Diabetes Association Guidelines in a Volunteer-run Free Clinic for the Uninsured in Providence, Rhode Island: Comparison with Standards Achieved ...  
  Ahmed Eldakrourey, Ericka Olivera, Rebecca Martin, Anne S. De Groot, Journal of Medicine and Health, Rhode Island. Rhode Island Medical Journal, 1/1/2013
• Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes  
  Leslie P. Cousens, Yan Su, Elizabeth McClaine, Xin Li, Frances Terry, Robert Smith, Jinhee Leed, William Martin, David W. Scott,, Anne S. De Groot, Experimental Diabetes Research. J Diabetes Res, 1/1/2013
• Join now to see all

Books/Book Chapters

• Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges 
  Chapter: Immunogenicity of Therapeutic Fusion proteins: Contributory Factors and Clinical Experience 
  Vibha Jawa; Leslie Cousens and De Groot ASEditors: Stefan R. Schmidt.John Wiley and Sons, Inc2013
• Development of Vaccines: From Discovery to Clinical Testing 
  Chapter: Tools for Vaccine Design: Prediction and Validation of Highly Immunogenic and Conserved Class II Epitopes and Development of Epitope-driven Vaccines 
  Groot AS, Ardito MA, Tassone, R, Knopf, P., Moise L. , and Martin WEditors: Indrish Srivastava and Manmohan Singh.John Wiley and Sons2011
• Methods in Microbiology: Immunology of Infection 
  Chapter: Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design 
  De Groot AS, Cohen T, Ardito M, Moise L, Martin B, Berzofsky JAEditors: Kaufmann S and Kabelitz D.Edition 3rd,2010
• Infectious Disease Informatics 
  Chapter: Immunoinformatics: The next step in vaccine design 
  Page 223 - 244Cohen T, Moise L, Martin W, DeGroot ASEditors: Sintchenko V.Springer, New York, NY2010
• Therapeutic Antibodies: from Theory to Practice 
  Chapter: Immunogenicity screening using in silico methods: Correlation between T-cell epitope content and clinical immunogenicity of monoclonal antibodies 
  Hai S, McMurry JA, Knopf P, Martin W, De Groot ASEditors: An Z and Strohl WR.John Wiley and Sons, New York, NY2009
• Clinical Applications of Immunomics 
  Chapter: Epitope-based Immunome-derived Vaccines: A Strategy for Improved Design and Safety 
  Page 36 - 69Anne S. De Groot, Julie McMurry, Lenny Moise, Bill MartinEditors: Falus, Andras.Springer Immunomics Series2009
• Vaccines for Biodefense and Emerging and Neglected Diseases 
  Chapter: Mycobacterium Tuberculosis Vaccines 
  De Groot ASEditors: Alan D.T. Barrett and Lawrence R. Stanberry.Elsevier2008
• Immunoinformatics 
  Chapter: Immunoinformatics applied to modifying and improving biological therapeutics 
  De Groot A.S., P. M. Knopf, D. Rivera and W. MartinEditors: Schonbach, Christian; Ranganathan, Shoba; Brusic, Vladimir.Kluwer publications2007
• Immunoinformatics. Series: Immunomics Reviews 
  Chapter: Immunoinformatics applied to modifying and improving biological therapeutics 
  De Groot A.S., P. M. Knopf, D. Rivera and W. MartinEditors: Schonbach, Christian; Ranganathan, Shoba; Brusic, Vladimir.Kluwer publications2007
• Correctional Perspectives. Views from Academics, Practitioners, and Prisoners 
  Chapter: Practitioner Perspective: Women Prisoners With HIV: A Letter From a Prison Doctor 
  De Groot ASEditors: Leanne Fiftal Alarid and Paul F. Cromwell.Oxford University Press2007
• Immunoinformatics. Series: Immunomics Reviews 
  Chapter: Immunoinformatics applied to modifying and improving biological therapeutics 
  De Groot A.S., P. M. Knopf, D. Rivera and W. MartinEditors: Schönbach, Christian; Ranganathan, Shoba; Brusic, Vladimir.Kluwer Publications2007
• Views from Academics, Practitioners, and Prisoners 
  Chapter: Practitioner Perspective: Women Prisoners With HIV: A Letter From a Prison Doctor, In Correctional Perspectives 
  De Groot ASEditors: Leanne Fiftal Alarid and Paul F. Cromwell.Oxford University Press2007
• State of the Art Analytical Methods for the Characterization of Biological Products and Assessment of Comparability 
  Chapter: De-immunization of therapeutic proteins by T cell epitope modification 
  Page 137 - 160De Groot A.S., P.M. Knopf, Bill MartinEditors: Mire-Sluis, A.Karger, Basel, Switzerland2005
• Frontiers in the Development of New Vaccines 
  Chapter: TB Vaccine Development: Opportunity and Imperative 
  De Groot AS, and McMurry JAEditors: Philippe Moingeon.Horizon Scientific Press Ltd2005
• CBI Proceedings 
  Chapter: Beyond Epitope Mapping: Making Vaccines and Modifying Therapeutics 
  De Groot A.S., Martin B., Marcon L., Knopf Pl, Rodriguez-Annon, C., Rivera D., Klutzer M., Boren C., Weiner, DWEditors: Akihiko Konagaya.Chem-Bio Informatics Society (CBI), Tokyo, Japan2005
• Managing Special Populations in Jails and Prisons 
  Chapter: Hepatitis B and hepatitis C among offenders within prisons 
  De Groot A.S. and Rachel MaddowEditors: Stan Stojkovic.Civic Research Group2005
• Health Issues of Incarcerated Women 
  Chapter: HIV Infection in Incarcerated Women 
  Maddow, R. and A.S. De GrootEditors: Ronald L. Braithwaite, Kimberly Jacob Arriola, Cassandra Newkirk.Rutgers University Press2005
• New Generation Vaccines 
  Chapter: High throughput informatics and in vitro assays for T cell epitope determination: Application to the design of epitope-driven vaccines 
  H. Sbai, De Groot A.S., J. Sidney, A. Sette and Jay A. BerzofskyEditors: Myron M. Levine, B. Kaper, Rino Rappuoli, Margaret Liu, Michael Good.Marcel Dekker Inc, New York, NYEdition 3rd,2004
• Immunogenicity of Therapeutic Biological Products. Developments in Biologicals 
  Chapter: Modeling the immunogenicity of therapeutic proteins using T cell epitope mapping 
  A.S. De Groot, J. Rayner, W. MartinEditors: Fred Brown, Anthony Mire Suis.Basel, Karger2003
• Treating HIV/AIDS in the Correctional Community 
  Chapter: Women in Prison. A Standard of HIV Care. In Reaching in, Reaching out 
  A.S. De Groot, S. LiebelEditors: Frederick Altice, P. Selywn, R. Watson.National Commission on Correctional Health Care, Chicago, IL2002
• Methods in Microbiology 
  Chapter: Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to vaccine design. Methods in Microbiology: Immunology of Infection 
  A.S. De Groot, H. Sbai, Bill Martin, and Jay A. BerzofskyEditors: Stefan Kaufmann and Dieter Kabelitz.Edition 2nd,2002
• Reaching in, Reaching out. Treating HIV/AIDS in the Correctional Community 
  Chapter: Women in Prison. A Standard of HIV Care 
  A.S. De Groot, S. LiebelEditors: Frederick Altice, P. Selywn, R. Watson.National Commission on Correctional Health Care, Chicago, IL2002
• Methods in Microbiology: Immunology of Infection 
  Chapter: Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to vaccine design 
  De Groot A.S., H. Sbai, Bill Martin, and Jay A. BerzofskyEditors: Stefan Kaufmann and Dieter Kabelitz.Edition 2nd,2002
• Correctional Perspectives: Views from Academics, Practitioners, and Prisoners 
  Chapter: Women Prisoners with HIV: An Open Letter from a Prison Doctor (1996) 
  De Groot A.S.Editors: Paul Cromwell and Leanne Fiftal Alarid.Roxbury Publishing Company2001
• Methods in Microbiology 
  Chapter: Prediction and determination of MHC ligands and T Cell Epitopes, Chapter 3, Immunology Methods 
  A.S. De Groot, Jesdale BM, Berzofsky JAEditors: SHE Kaufmann.Academic Press, New York, NY1998
• Join now to see all

Abstracts/Posters

• Development of Community-led Education Interventions for Human Papillomavirus Vaccination as a Model for Future HIV Vaccination Campaigns
  Karamoko Tounkara, Ibrahima Teguete, Eliza Squibb, Ben Aboubacar, Kotou Sangare, Sarah Beseme, Ousmane Koita, International Symposium for HIV and Emerging Infectious Diseases, Marseille, France, 1/25/2016
• Development of community-led education about Human papillomavirus vaccination as a model for future HIV vaccination campaigns
  Karamoko Tounkara, Ibrahima Teguete, Eliza Squibb, Ben Aboubacar, Kotou Sangare, Sarah Beseme, Ousmane Koita, 15th European AIDS Conference, Barcelona, Spain, 1/21/2015
• Assessment of HPV and cervical cancer knowledge, attitudes, practices and willingness to participate in an HPV vaccination program in Bamako, Mali
  Karamoko Tounkara, Ibrahima Teguete, Eliza Squibb, Ben Aboubacar, Youssouf Kone, Kotou Sangare, Sarah Beseme, Jennifer S. Smith, Ousmane Koita, A. S. De Groot, 30th International Papillomavirus Conference and Clinical and Public Health Workshops, Lisbon, Potrugal, 1/17/2015
• A large scale cervical cancer screening campaign in Bamako, Mali
  Ibrahima Teguete, Ousmane Koita, Karamoko Tounkara, Ben Aboubacar, Kotou Sangare, Eliza Squibb, Sarah Beseme, Jennifer S. Smith, A. S. De Groot, 30th International Papillomavirus Conference and Clinical and Public Health Workshops, Lisbon, Potrugal, 1/17/2015
• Impact of community-led education on knowledge of HPV, cervical caner and willingness to participate in HPV vaccination in Bamako, Mali
  Eliza Squibb, Ibrahima Teguete, Karamoko Tounkara, Ben Aboubacar, Kotou Sangare, Sarah Beseme, Jennifer S. Smith, Ousmane Koita, A. S. De Groot, 30th International Papillomavirus Conference and Clinical and Public Health Workshops, Lisbon, Potrugal, 1/17/2015
• T-Cell Dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation
  L.P. Cousens, V. Jawa, M. Awwad, E. Wakshull, H. Kropshofer, W. Martin, A.S. De Groot, National Biotechnology Conference, San Diego, CA, 1/1/2014
• Albumin Delivery of Tregitope Peptides for Tolerance Induction in Autoimmunity and Inflammatory Disease
  L.P. Cousens, M. Perkins, F. Antunes, M. Marshall, D. Shelly, W. Martin, A.S. De Groot, National Biotechnology Conference, San Diego, CA, 1/1/2014
• Tregitope Applications to Tolerance Induction in Autoimmune Disease and Therapeutic Protein Immunogenicity
  L.P. Cousens1, A.S. De Groot1,2, F. Mingozzi3,4, D. Koeberl, W. Elyaman6, B. Mazer7, S. Khoury5, and W. Martin, National Biotechnology Conference, San Diego, CA, 1/1/2014
• Regulating Immune Responses to Biologics: Validation of Screening, Deimmunization and Tolerization Approaches
  L.P. Cousens, L. Moise, F. Terry, W. Martin, and A.S. De Groot, National Biotechnology Conference, San Diego, CA, 1/1/2014
• Tolerization as a Rational Design Approach for Reducing the Immunogenicity of Biologics
  A.S. De Groot, A.J. Vincelli, F. E. Terry, L.P. Cousens, J.M. Tivin, R. F. Martin, and W. D. Martin, National Biotechnology Conference, San Diego, CA, 1/1/2014
• T-Cell Dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation
  L.P. Cousens, V. Jawa, M. Awwad, E. Wakshull, H. Kropshofer, W. Martin, A.S. De Groot, AAPS; National Biotechnology Conference, San Diego, CA, 1/1/2014
• Albumin Delivery of Tregitope Peptides for Tolerance Induction in Autoimmunity and Inflammatory Disease
  L.P. Cousens, M. Perkins, F. Antunes, M. Marshall, D. Shelly, W. Martin, A.S. De Groot, AAPS; National Biotechnology Conference, San Diego, CA, 1/1/2014
• Tregitope Applications to Tolerance Induction in Autoimmune Disease and Therapeutic Protein Immunogenicity
  L.P. Cousens, A.S. De Groot, F. Mingozzi, D. Koeberl, W. Elyaman, B. Mazer, S. Khoury, and W. Martin, AAPS; National Biotechnology Conference, San Diego, CA, 1/1/2014
• Regulating Immune Responses to Biologics: Validation of Screening, Deimmunization and Tolerization Approaches
  L.P. Cousens, L. Moise, F. Terry, W. Martin, and A.S. De Groot, AAPS; National Biotechnology Conference, San Diego, CA, 1/1/2014
• Tolerization as a Rational Design Approach for Reducing the Immunogenicity of Biologics
  A.S. De Groot, A.J. Vincelli, F. E. Terry, L.P. Cousens, J.M. Tivin, R. F. Martin, and W. D. Martin, AAPS; National Biotechnology Conference, San Diego, CA, 1/1/2014
• Immunogenicity assessment of in silico-selected T cell epitopes for a Burkholderia biodefense vaccine
  Liu R, Martin BA, Desrosiers J, Moise L, De Groot AS, American Society for Microbiology (ASM) Biodefense and Emerging Diseases Research Meeting, Washington, DC, 1/25/2013
• Immunogenicity assessment of in silico-selected T cell epitopes for a Burkholderia biodefense vaccine
  Liu R, Desrosiers J, Martin BA, Moise L, De Groot AS, National Foundation for Infectious Disease (NFID) 16th Annual Conference on Vaccine Research, Baltimore, MD, 1/22/2013
• Immunogenicity assessment of in silico-selected T cell epitopes for a Burkholderia biodefense vaccine
  Liu R, Martin BA, Desrosiers J, Moise L, De Groot AS, American Society for Microbiology (ASM) Biodefense and Emerging Diseases Research Meeting; National Foundation for Infectious Disease (NFID) 16th Annual Conference on Vaccine Research, Washington, DC (2013); Baltimore, MD (2013), 1/22/2013
• Immunogenicity and protective efficacy of a multi-epitope vaccine composed of Ebola virus and Venezuelan Equine Encephalitis Virus HLA class II T-cell epitopes in HLA ...
  Dupuy LC, Mitchell D, Richards MJ, Bounds C, Ardito M, McClaine E, Moise L, Martin W, De Groot AS, Schmaljohn CS, National Foundation for Infectious Disease (NFID) 16th Annual Conference on Vaccine Research, Baltimore, MD, 1/22/2013
• CD4+ T Cell Responses to Cross-Reactive Influenza H1N1 T-cell Epitopes Identified by Immunoinformatic Methods
  Moise L, Boyle C, Latimer H, Tassone R, Ardito M, Terry F, Martin WD, De Groot AS, National Foundation for Infectious Disease (NFID) 16th Annual Conference on Vaccine Research, Baltimore, MD, 1/22/2013
• H. pylori vaccine development by reverse vaccinology
  Zhang S, Moise L, Terry F, Desrosiers J, Aponte J, Fast L, Martin W, De Groot AS, Moss S., National Foundation for Infectious Disease (NFID) 16th Annual Conference on Vaccine Research, Baltimore, MD, 1/22/2013
• Regulatory T cell epitopes in IgG (Tregitopes) suppress immune responses without skewing toward TH2
  Su Y, Cousens L, De Groot A, Scott DW, 15th Annual International Congress of Immunology, Milan, Italy, 1/22/2013
• In silico prediction of HLA-DP and -DQ epitope content is poorly correlated with clinical immunogenicity of therapeutic proteins
  De Groot AS, Tassone R, Cousens LP, Terry F, Martin R, Ardito M, Martin W, American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC), San Diego, CA, 1/20/2013
• Tregitopes: The active ingredient in IVIG-mediated tolerance induction?
  Cousens LP, Moise L, Martin W, De Groot AS, American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC), San Diego, CA, 1/20/2013
• Antigen-specific tolerance induction by Tregitopes in vivo
  De Groot AS, Cousens LP, Moise L, Najafian N, Mingozzi F, Elyaman W, Mazer B, Khoury S, Su Y, Scott DW, Martin W, American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference (NBC), San Diego, CA, 1/20/2013
• Join now to see all

Lectures

• Personalized Medicine for Biologics: Does HLA play a role in Immunogenicity? 
  Instituto Gulbenkian de Ciencia, Oeiras, Lisbon, Portugal - 1/23/2015
• The Two-faced T cell epitope and the role of "Sel" and "Other" in Vaccine Efficacy 
  Netherlands National Institute for Public Health and the Environment (RIVM) and IntraVacc, Utrecht, - 1/18/2015
• Tregitope Mediated Tolerance: The Role of HLA 
  Rotterdam, Netherlands - 1/17/2015
• Discovery and validation of homologous T cell epitopes in pathogens and humans: What implications for vaccines? 
  Les Pensieres, Annecy, France - 1/8/2015
• The Two-faced T cell epitope and the role of "Self" and "Other" in Vaccines and Therapeutics 
  1/24/2014
• Tregitope: The Immune System Off Switch and …Testing the Limits of Epitope-mapping tools: Can we predict Tolerance? 
  1/14/2014
• Influenza Vaccine Design: Role of Cross-Reactivity to “Self” and “Other” when Designing Vaccines and Therapeutics 
  1/14/2014
• Influenza Vaccine Design: Role of Cross-Reactivity to "Self" and "Other" when Designing Vaccines and Therapeutics 
  1/14/2014
• H7N9 Influenza and Immune Camouflage, a new mechanism of immune escape 
  1/13/2014
• The Science and potential of Tregitope-Albumin Fusions to induce tolerance to protein drugs, transplants, and blood replacement therapies, as well as for the treatment... 
  Nottingham, England, UK - 1/1/2014
• T-cell Dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation 
  San Diego, CA - 1/1/2014
• Immunogenicity and Tolerance 
  1/1/2014
• Tregitopes 
  San Diego, CA - 1/30/2013
• From Gene to Vaccine 
  Grand Hyatt, Washington, DC - 1/28/2013
• The Two-faced T cell epitope: Relevance to Vaccine Efficacy and Design 
  Barcelona, Sitges, Spain - 1/27/2013
• Immunogenicity 
  Hyatt Resort and Spa, Huntington Beach, CA - 1/25/2013
• FDA Brown Bag Lunch: The Two Faced T cell epitope: Implications for Immunogenicity 
  1/25/2013
• Innovation in Therapeutics: Drugs of the Future 
  1/21/2013
• Immunogenicity Screening, Deimmunization, Tolerance Induction for Biologics 
  San Diego, CA - 1/20/2013
• Influenza Vaccine Immunogenicity – The story of H1N1 
  1/20/2013
• Influenza Vaccine Immunogenicity - The story of H1N1 
  1/20/2013
• Tregitopes an Immunomodulation Powerhouse: Alternative to IVIG 
  Chicago, IL - 1/18/2013
• The Two-faced T cell epitope: Relevance to Vaccine and Biologics Efficacy and Design 
  Port Saint Lucie, FL - 1/13/2013
• MHC epitope mapping in humans and development of tools specific to domestic and livestock species 
  1/9/2013
• Vaccine Design - Targeting the Immune System 
  1/9/2013
• Join now to see all

Other

• Writings from West Africa 
  A. S. De Groot, GAIA Vaccine Foundation Website
  http://blog.gaiavaccine.org/
  1/1/2015
• Thinking Out Loud (Blog on Immunogenicity, Biotherapeutics and Vaccines) 
  A. S. De Groot
  http://www.epivax.com/blog/
  1/1/2015
• Methods for Addressing Immunogenicity in Therapeutic Enzymes 
  Cousens LP, Moise L, De Groot AS, Biobetters, AAPS Advances. American Association of Pharmaceutical Scientists 2015 in the Pharmaceuti
  1/1/2015
• EpiVax toolkit to be used by Japanese biopharmaceutical firm 
  De Groot AS
  1/30/14
• EpiVax toolkit to be used by Japanese biopharmaceutical URI professor wins grant to launch cervical cancer prevention campaign in West Africa using storytelling cloth ... 
  Gabrielle Porter
  1/30/2014
• Vaccine nearer for H. pylori pathogen 
  Harold Ambler
  1/28/2014
• On why the NIH budget cuts have affected the Ebola vaccine efforts 
  De Groot AS, PolitiFact
  http://www.providencejournal.com/news/health/20141013-money-quicker-response-needed-to-fight-ebola-other-diseases-experts-at-ri-conference-say
  1/18/2014
• De Groot pursues Ebola research 
  Providence Business News
  1/18/2014
• PolitiFact - On why the NIH budget cuts have affected the Ebola vaccine efforts 
  
  http://www.providencejournal.com/news/health/20141013-money-quicker-response-needed-to-fight-ebola-other-diseases-experts-at-ri-conference-say.ece
  1/18/2014
• Clinica Esperanza/Hope Clinic receives $50K grant from BCBSRI 
  Providence Business News
  1/16/2014
• EpiVax develops immunogenicity tool with URI, Dartmouth 
  Kaylen Auer, Providence Business News
  1/16/2014
• RI conference that US is ripe for Ebola outbreak 
  De Groot AS, Providence Journal
  http://www.providencejournal.com/news/content/20141014-doctor-tells-providence-conference-that-u.s.-is-ripe-for-ebola-outbreak
  1/14/2014
• Doctor [Does Not] tell [s] RI conference that US is ripe for Ebola outbreak 
  Providence Journal
  http://www.providencejournal.com/news/content/20141014-doctor-tells-providence-conference-that-u.s.-is-ripe-for-ebola-outbreak.ece
  1/14/2014
• New research, same mission: 'improve human health' 
  De Groot AS
  1/13/2014
• Vaccine for Ebola (was not) (in fact) other diseases (were) focus of conference 
  De Groot AS, Channel 12
  http://wpri.com/2014/10/13/ebola-outbreak-at-center-of-ri-vaccine-conference/
  1/13/2014
• Ebola (was not the) topic of discussion at vaccine conference 
  De Groot AS, Channel 10
  http://www.turnto10.com/story/26772659/ebola-topic-of-discussion-at-vaccine-conference-in-ri
  1/13/2014
• New research, same mission: ‘improve human health’ 
  Harold Ambler
  1/13/2014
• Money, quicker response needed to fight Ebola, other diseases, experts at RI conference say 
  Providence Journal
  http://www.providencejournal.com/news/health/20141013-money-quicker-response-needed-to-fight-ebola-other-diseases-experts-at-ri-conference-say.ece
  1/13/2014
• Vaccine for Ebola [was not] [in fact] other diseases [were] focus of conference 
  Susan Campbell, Channel 12
  http://wpri.com/2014/10/13/ebola-outbreak-at-center-of-ri-vaccine-conference/
  1/13/2014
• Ebola [was not the] topic of discussion at vaccine conference 
  Mario Hilario, Channel 10
  http://www.turnto10.com/story/26772659/ebola-topic-of-discussion-at-vaccine-conference-in-ri
  1/13/2014
• Five Questions With: Dr. Anne De Groot 
  Harold Ambler
  1/10/2014
• De Groot named one of most influential people in vaccine industry 
  Providence Business News
  1/9/2014
• URI professor wins grant to launch cervical cancer prevention campaign in West Africa using storytelling cloth 
  Patricia Daddona, Providence Business News
  1/6/2014
• Ebola Interviews 
  Channel 12 WPRI
  http://wpri.com/2014/10/15/disease-expert-we-need-to-concentrate-on-west-africa/
  1/1/2014
• Study: Clinica Esperanza clinic will save 1.3M US dollars in ER visits 
  De Groot AS
  1/18/2013
• Join now to see all